TRICLIP™ TRICUSPID VALVE REPAIR CLINICAL DATA
TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.
TRICLIP™ TRICUSPID VALVE REPAIR CLINICAL DATA
TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.
IMPROVING QUALITY OF LIFE
WITHOUT COMPROMISE2
The TRILUMINATE™ Pivotal Trial demonstrated that TriClip TEER therapy was superior to medical therapy alone in improving quality of life and reducing tricuspid regurgitation.
Remarkable and Sustained TR Reduction2
TR Grade (Core Lab)
- Extremely Safe Profile at 30-days2
98.3%
FREEDOM
FROM MAEs0.6%
NEW PACEMAKER
IMPLANTATION0%
DEVICE THROMBUS
99.4%
SURVIVAL
0%
NONELECTIVE CV
SURGERY FROM
DEVICE-RELATED AE0%
DEVICE EMBOLIZATION
- Significant Improvement in Quality of Life and Functional Status at 30-days2
- Baseline Population Characteristics2
71%
OF PATIENTS HAD MASSIVE
OR TORRENTIAL TR4.4±0.7cm
TRICUSPID VALVE
ANNULUS DIAMETER>35%
OF PATIENTS WITH PRIOR
VALVULAR INTERVENTION15%
OF PATIENTS HAD A CRT, CRT-D, ICD,
OR PERMANENT PACEMAKER
TRILUMINATE PIVOTAL TRIAL DATA CARD
Get the latest data from the TRILUMINATE Pivotal Trial in a one-pager PDF format.
PROVEN ACROSS A BROAD
RANGE OF ANATOMIES7,8
The bRIGHT Study demonstrated that TriClip™ TEER significantly reduced TR across a broad range of anatomies - in a safe and effective procedure - resulting in durable and meaningful clinical outcomes.
Designed to Maximize TR Reduction7
TR Grade (Core Lab)
- Successfully Treated a Broad Range of Anatomies8
- Proven Durability Backed by Clinical Data7
NYHA Functional Class
KCCQ - OS
- TriClip TEER demonstrated Procedural Success and a Strong Safety Profile5
HIGH PROCEDURAL
SUCCESS98%
Implant
sucess rateSHORT
DEVICE TIME
78±41
Minutes
HIGH SAFETY
PROFILE
99%
Freedom
from MAEs
99.7% survival at 30 days1.3% reintervention
0% embolization
bRIGHT STUDY DATA CARD
Get the latest data from the bRIGHT Study in a one-pager PDF format.
PROVEN SAFETY AND EFFECTIVENESS
The TRILUMINATE™ Trial proved that TriClip TEER safely and effectively reduces TR and HF hospitalizations.
93%
SURVIVAL
AT 1 YR3
100%
IMPLANT
SUCCESS4
91%
ACUTE PROCEDURAL
SUCCESS RATE4
0%
STROKE4
0%
CONVERSION TO
SURGERY4
- Significant and Durable TR Reduction4
Durable reduction in tricuspid regurgitation (TR)
- Significant improvement in function and quality of life3
Durable improvements in NYHA
20 Points significant improvement in KCCQ-OS health-related quality of life at one-year - TriClip TEER demonstrated a high safety profile4
High survival in a
fragile patient population93%
Survival
at 1 yearLow rates of
major adverse events93%
Freedom from MAEs
at 1 year - Significant reduction in hospitalizations4
Reduced hospitalization rate
TRILUMINATE TRIAL DATA CARD
Get the latest data from the TRILUMINATE Trial in a one-pager PDF format.
MAT-2006556 v9.0 | Item approved for OUS use only.